179 related articles for article (PubMed ID: 30131069)
1. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
4. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
5. Expression of Nestin and CD133 in serous ovarian carcinoma.
Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
[TBL] [Abstract][Full Text] [Related]
6. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
7. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
9. Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis.
Trudel D; Desmeules P; Turcotte S; Plante M; Grégoire J; Renaud MC; Orain M; Bairati I; Têtu B
Mod Pathol; 2014 Oct; 27(10):1394-404. PubMed ID: 24603589
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis.
Desmeules P; Trudel D; Turcotte S; Sirois J; Plante M; Grégoire J; Renaud MC; Orain M; Têtu B; Bairati I
Hum Pathol; 2015 May; 46(5):739-45. PubMed ID: 25771900
[TBL] [Abstract][Full Text] [Related]
11. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
[TBL] [Abstract][Full Text] [Related]
13. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
14. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
Djordjevic B; Malpica A
Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
[TBL] [Abstract][Full Text] [Related]
15. The life and times of low-grade serous carcinoma of the ovary.
Gershenson DM
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714500
[TBL] [Abstract][Full Text] [Related]
16. STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
Huvila J; Cochrane DR; Ta M; Chow C; Greening K; Leung S; Karnezis AN; DiFeo A; Huntsman DG
J Pathol Clin Res; 2021 Nov; 7(6):548-555. PubMed ID: 34138519
[TBL] [Abstract][Full Text] [Related]
17. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
18. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
20. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]